Prognostic pulmonary arterial hypertension risk stratification scores of the study population
| Model . | Score format (x/x/x …) . | 1-year . | 3-year . | 5-year . | |||||
|---|---|---|---|---|---|---|---|---|---|
| SPAHR/COMPERA—(SPAHR equation) . | n (169) . | Baseline . | n (604) . | Follow-up . | n (450) . | Follow-up . | n (352) . | Follow-up . | |
| 3–11 parameters, original SPAHR/COMPERA | (1/2/3) | 169 | 28/120/21 | 604 | 261/300/43 | 450 | 245/192/13 | 352 | 227/120/5 |
| 3–11 parameters, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 169 | 28/55/65/21 | 604 | 261/182/118/43 | 450 | 245/136/56/13 | 352 | 227/87/33/5 |
| ¤ 3–11 parameter, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 169 | 28/119/22 | 604 | 259/302/43 | 450 | 244/193/13 | 352 | 226/121/5 |
| ¤ 3–11 parameters, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 169 | 28/54/65/22 | 604 | 259/180/122/43 | 450 | 244/135/58/13 | 352 | 226/87/34/5 |
| Bi-parametric SPAHR/COMPERA—(SPAHR equation) | |||||||||
| NT-proBNP and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 125 | 10/48/67 | 474 | 149/225/100 | 347 | 145/168/34 | 276 | 141/117/18 |
| ¤ NT-proBNP and WHO-FC, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 125 | 10/41/74 | 474 | 149/212/113 | 347 | 145/160/42 | 276 | 141/112/23 |
| NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 125 | 10/15/33/67 | 474 | 149/136/89/100 | 347 | 145/117/51/34 | 276 | 141/87/30/18 |
| ¤ NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 125 | 10/14/27/74 | 474 | 149/124/88/113 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| NT-proBNP and 6MWD, original SPAHR/COMPERA | (1/2/3) | 113 | 6/37/70 | 462 | 112/220/130 | 350 | 112/183/55 | 282 | 111/140/31 |
| ¤ NT-proBNP and 6MWD, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 113 | 6/31/76 | 462 | 112/203/147 | 350 | 112/170/68 | 282 | 111/132/39 |
| NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 113 | 6/11/26/70 | 462 | 112/104/116/130 | 350 | 112/94/89/55 | 282 | 111/84/56/31 |
| ¤ NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 113 | 6/10/21/76 | 462 | 112/100/103/147 | 350 | 112/90/80/68 | 282 | 111/80/52/39 |
| 6MWD and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 136 | 10/92/34 | 508 | 147/296/65 | 383 | 145/218/20 | 302 | 142/154/6 |
| 6MWD and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
| COMPERA 2.0 | |||||||||
| COMPERA 2.0 | (1/2/3/4) | 113 | 11/15/68/19 | 447 | 154/134/114/45 | 337 | 151/111/62/12 | 270 | 150/82/35/3 |
| Bi-parameter (NT-proBNP and 6MWD) | (1/2/3/4) | 113 | 6/14/32/61 | 462 | 112/135/95/120 | 350 | 112/120/64/54 | 282 | 111/103/39/29 |
| Bi-parameter (NT-proBNP and WHO-FC) | (1/2/3/4) | 125 | 10/14/29/72 | 474 | 149/124/91/110 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| Bi-parameter (6MWD and WHO-FC) | (1/2/3/4) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
| Model . | Score format (x/x/x …) . | 1-year . | 3-year . | 5-year . | |||||
|---|---|---|---|---|---|---|---|---|---|
| SPAHR/COMPERA—(SPAHR equation) . | n (169) . | Baseline . | n (604) . | Follow-up . | n (450) . | Follow-up . | n (352) . | Follow-up . | |
| 3–11 parameters, original SPAHR/COMPERA | (1/2/3) | 169 | 28/120/21 | 604 | 261/300/43 | 450 | 245/192/13 | 352 | 227/120/5 |
| 3–11 parameters, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 169 | 28/55/65/21 | 604 | 261/182/118/43 | 450 | 245/136/56/13 | 352 | 227/87/33/5 |
| ¤ 3–11 parameter, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 169 | 28/119/22 | 604 | 259/302/43 | 450 | 244/193/13 | 352 | 226/121/5 |
| ¤ 3–11 parameters, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 169 | 28/54/65/22 | 604 | 259/180/122/43 | 450 | 244/135/58/13 | 352 | 226/87/34/5 |
| Bi-parametric SPAHR/COMPERA—(SPAHR equation) | |||||||||
| NT-proBNP and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 125 | 10/48/67 | 474 | 149/225/100 | 347 | 145/168/34 | 276 | 141/117/18 |
| ¤ NT-proBNP and WHO-FC, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 125 | 10/41/74 | 474 | 149/212/113 | 347 | 145/160/42 | 276 | 141/112/23 |
| NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 125 | 10/15/33/67 | 474 | 149/136/89/100 | 347 | 145/117/51/34 | 276 | 141/87/30/18 |
| ¤ NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 125 | 10/14/27/74 | 474 | 149/124/88/113 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| NT-proBNP and 6MWD, original SPAHR/COMPERA | (1/2/3) | 113 | 6/37/70 | 462 | 112/220/130 | 350 | 112/183/55 | 282 | 111/140/31 |
| ¤ NT-proBNP and 6MWD, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 113 | 6/31/76 | 462 | 112/203/147 | 350 | 112/170/68 | 282 | 111/132/39 |
| NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 113 | 6/11/26/70 | 462 | 112/104/116/130 | 350 | 112/94/89/55 | 282 | 111/84/56/31 |
| ¤ NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 113 | 6/10/21/76 | 462 | 112/100/103/147 | 350 | 112/90/80/68 | 282 | 111/80/52/39 |
| 6MWD and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 136 | 10/92/34 | 508 | 147/296/65 | 383 | 145/218/20 | 302 | 142/154/6 |
| 6MWD and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
| COMPERA 2.0 | |||||||||
| COMPERA 2.0 | (1/2/3/4) | 113 | 11/15/68/19 | 447 | 154/134/114/45 | 337 | 151/111/62/12 | 270 | 150/82/35/3 |
| Bi-parameter (NT-proBNP and 6MWD) | (1/2/3/4) | 113 | 6/14/32/61 | 462 | 112/135/95/120 | 350 | 112/120/64/54 | 282 | 111/103/39/29 |
| Bi-parameter (NT-proBNP and WHO-FC) | (1/2/3/4) | 125 | 10/14/29/72 | 474 | 149/124/91/110 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| Bi-parameter (6MWD and WHO-FC) | (1/2/3/4) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
¤ indicates new NT-proBNP cut-offs.22
6MWD, 6-min walking distance; AUC, area under the ROC curve; COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SPAHR, Swedish Pulmonary Arterial Hypertension Registry; WHO-FC, World Health Organization Functional Class.
Prognostic pulmonary arterial hypertension risk stratification scores of the study population
| Model . | Score format (x/x/x …) . | 1-year . | 3-year . | 5-year . | |||||
|---|---|---|---|---|---|---|---|---|---|
| SPAHR/COMPERA—(SPAHR equation) . | n (169) . | Baseline . | n (604) . | Follow-up . | n (450) . | Follow-up . | n (352) . | Follow-up . | |
| 3–11 parameters, original SPAHR/COMPERA | (1/2/3) | 169 | 28/120/21 | 604 | 261/300/43 | 450 | 245/192/13 | 352 | 227/120/5 |
| 3–11 parameters, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 169 | 28/55/65/21 | 604 | 261/182/118/43 | 450 | 245/136/56/13 | 352 | 227/87/33/5 |
| ¤ 3–11 parameter, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 169 | 28/119/22 | 604 | 259/302/43 | 450 | 244/193/13 | 352 | 226/121/5 |
| ¤ 3–11 parameters, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 169 | 28/54/65/22 | 604 | 259/180/122/43 | 450 | 244/135/58/13 | 352 | 226/87/34/5 |
| Bi-parametric SPAHR/COMPERA—(SPAHR equation) | |||||||||
| NT-proBNP and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 125 | 10/48/67 | 474 | 149/225/100 | 347 | 145/168/34 | 276 | 141/117/18 |
| ¤ NT-proBNP and WHO-FC, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 125 | 10/41/74 | 474 | 149/212/113 | 347 | 145/160/42 | 276 | 141/112/23 |
| NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 125 | 10/15/33/67 | 474 | 149/136/89/100 | 347 | 145/117/51/34 | 276 | 141/87/30/18 |
| ¤ NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 125 | 10/14/27/74 | 474 | 149/124/88/113 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| NT-proBNP and 6MWD, original SPAHR/COMPERA | (1/2/3) | 113 | 6/37/70 | 462 | 112/220/130 | 350 | 112/183/55 | 282 | 111/140/31 |
| ¤ NT-proBNP and 6MWD, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 113 | 6/31/76 | 462 | 112/203/147 | 350 | 112/170/68 | 282 | 111/132/39 |
| NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 113 | 6/11/26/70 | 462 | 112/104/116/130 | 350 | 112/94/89/55 | 282 | 111/84/56/31 |
| ¤ NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 113 | 6/10/21/76 | 462 | 112/100/103/147 | 350 | 112/90/80/68 | 282 | 111/80/52/39 |
| 6MWD and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 136 | 10/92/34 | 508 | 147/296/65 | 383 | 145/218/20 | 302 | 142/154/6 |
| 6MWD and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
| COMPERA 2.0 | |||||||||
| COMPERA 2.0 | (1/2/3/4) | 113 | 11/15/68/19 | 447 | 154/134/114/45 | 337 | 151/111/62/12 | 270 | 150/82/35/3 |
| Bi-parameter (NT-proBNP and 6MWD) | (1/2/3/4) | 113 | 6/14/32/61 | 462 | 112/135/95/120 | 350 | 112/120/64/54 | 282 | 111/103/39/29 |
| Bi-parameter (NT-proBNP and WHO-FC) | (1/2/3/4) | 125 | 10/14/29/72 | 474 | 149/124/91/110 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| Bi-parameter (6MWD and WHO-FC) | (1/2/3/4) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
| Model . | Score format (x/x/x …) . | 1-year . | 3-year . | 5-year . | |||||
|---|---|---|---|---|---|---|---|---|---|
| SPAHR/COMPERA—(SPAHR equation) . | n (169) . | Baseline . | n (604) . | Follow-up . | n (450) . | Follow-up . | n (352) . | Follow-up . | |
| 3–11 parameters, original SPAHR/COMPERA | (1/2/3) | 169 | 28/120/21 | 604 | 261/300/43 | 450 | 245/192/13 | 352 | 227/120/5 |
| 3–11 parameters, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 169 | 28/55/65/21 | 604 | 261/182/118/43 | 450 | 245/136/56/13 | 352 | 227/87/33/5 |
| ¤ 3–11 parameter, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 169 | 28/119/22 | 604 | 259/302/43 | 450 | 244/193/13 | 352 | 226/121/5 |
| ¤ 3–11 parameters, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 169 | 28/54/65/22 | 604 | 259/180/122/43 | 450 | 244/135/58/13 | 352 | 226/87/34/5 |
| Bi-parametric SPAHR/COMPERA—(SPAHR equation) | |||||||||
| NT-proBNP and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 125 | 10/48/67 | 474 | 149/225/100 | 347 | 145/168/34 | 276 | 141/117/18 |
| ¤ NT-proBNP and WHO-FC, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 125 | 10/41/74 | 474 | 149/212/113 | 347 | 145/160/42 | 276 | 141/112/23 |
| NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 125 | 10/15/33/67 | 474 | 149/136/89/100 | 347 | 145/117/51/34 | 276 | 141/87/30/18 |
| ¤ NT-proBNP and WHO-FC, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 125 | 10/14/27/74 | 474 | 149/124/88/113 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| NT-proBNP and 6MWD, original SPAHR/COMPERA | (1/2/3) | 113 | 6/37/70 | 462 | 112/220/130 | 350 | 112/183/55 | 282 | 111/140/31 |
| ¤ NT-proBNP and 6MWD, original SPAHR/COMPERA, new cut-offs | (1/2/3) | 113 | 6/31/76 | 462 | 112/203/147 | 350 | 112/170/68 | 282 | 111/132/39 |
| NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 113 | 6/11/26/70 | 462 | 112/104/116/130 | 350 | 112/94/89/55 | 282 | 111/84/56/31 |
| ¤ NT-proBNP and 6MWD, updated SPAHR, divided intermediate risk, new cut-offs | (1/1.75/2.25/3) | 113 | 6/10/21/76 | 462 | 112/100/103/147 | 350 | 112/90/80/68 | 282 | 111/80/52/39 |
| 6MWD and WHO-FC, original SPAHR/COMPERA | (1/2/3) | 136 | 10/92/34 | 508 | 147/296/65 | 383 | 145/218/20 | 302 | 142/154/6 |
| 6MWD and WHO-FC, updated SPAHR, divided intermediate risk | (1/1.75/2.25/3) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
| COMPERA 2.0 | |||||||||
| COMPERA 2.0 | (1/2/3/4) | 113 | 11/15/68/19 | 447 | 154/134/114/45 | 337 | 151/111/62/12 | 270 | 150/82/35/3 |
| Bi-parameter (NT-proBNP and 6MWD) | (1/2/3/4) | 113 | 6/14/32/61 | 462 | 112/135/95/120 | 350 | 112/120/64/54 | 282 | 111/103/39/29 |
| Bi-parameter (NT-proBNP and WHO-FC) | (1/2/3/4) | 125 | 10/14/29/72 | 474 | 149/124/91/110 | 347 | 145/107/53/42 | 276 | 141/80/32/23 |
| Bi-parameter (6MWD and WHO-FC) | (1/2/3/4) | 136 | 10/21/31/74 | 508 | 147/191/105/65 | 383 | 145/157/61/20 | 302 | 142/115/39/6 |
¤ indicates new NT-proBNP cut-offs.22
6MWD, 6-min walking distance; AUC, area under the ROC curve; COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; SPAHR, Swedish Pulmonary Arterial Hypertension Registry; WHO-FC, World Health Organization Functional Class.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
